172 related articles for article (PubMed ID: 3805726)
1. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
Livingston PO; Calves MJ; Natoli EJ
J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
[TBL] [Abstract][Full Text] [Related]
2. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
[TBL] [Abstract][Full Text] [Related]
3. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
[TBL] [Abstract][Full Text] [Related]
4. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
Livingston PO; Natoli EJ; Calves MJ; Stockert E; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1987 May; 84(9):2911-5. PubMed ID: 3472242
[TBL] [Abstract][Full Text] [Related]
5. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
[TBL] [Abstract][Full Text] [Related]
6. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
Livingston PO
Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
[TBL] [Abstract][Full Text] [Related]
7. A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity.
Natoli EJ; Livingston PO; Pukel CS; Lloyd KO; Wiegandt H; Szalay J; Oettgen HF; Old LJ
Cancer Res; 1986 Aug; 46(8):4116-20. PubMed ID: 3731079
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies.
Ohta S; Igarashi S; Honda A; Sato S; Hanai N
Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645
[TBL] [Abstract][Full Text] [Related]
9. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
[TBL] [Abstract][Full Text] [Related]
10. Specific serological response by active immunization with GD3-bearing liposomes.
Massó O; Aliño SF; Lejarreta M; Blasco F; Piulats J
J Pharmacol Exp Ther; 1996 Sep; 278(3):1114-20. PubMed ID: 8819493
[TBL] [Abstract][Full Text] [Related]
11. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
12. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728
[TBL] [Abstract][Full Text] [Related]
13. Ganglioside vaccines with emphasis on GM2.
Livingston P
Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
[TBL] [Abstract][Full Text] [Related]
14. Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.
Vrionis FD; Wikstrand CJ; Fredman P; Månsson JE; Svennerholm L; Bigner DD
Cancer Res; 1989 Dec; 49(23):6645-51. PubMed ID: 2479468
[TBL] [Abstract][Full Text] [Related]
15. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
[TBL] [Abstract][Full Text] [Related]
16. Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides from Camplyobacter jejuni.
Ritter G; Fortunato SR; Cohen L; Noguchi Y; Bernard EM; Stockert E; Old LJ
Int J Cancer; 1996 Apr; 66(2):184-90. PubMed ID: 8603809
[TBL] [Abstract][Full Text] [Related]
17. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse.
Livingston PO; Ritter G; Calves MJ
Cancer Immunol Immunother; 1989; 29(3):179-84. PubMed ID: 2731184
[TBL] [Abstract][Full Text] [Related]
18. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
20. Experimental and clinical studies with active specific immunotherapy.
Livingston PO
Prog Clin Biol Res; 1989; 288():309-21. PubMed ID: 2654953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
